{"id":307582,"date":"2025-07-15T21:37:51","date_gmt":"2025-07-15T21:37:51","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling-2\/"},"modified":"2025-07-15T21:37:51","modified_gmt":"2025-07-15T21:37:51","slug":"biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/","title":{"rendered":"Biyofarmas\u00f6tik Firman\u0131n Hisseleri Olumlu Patent Karar\u0131n\u0131n Ard\u0131ndan Y\u00fckseldi"},"content":{"rendered":"
<\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":45,"featured_media":307568,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[4674],"tags":[28,39,40],"class_list":["post-307582","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-investment","tag-platform","tag-signal"],"acf":{"h1":"Liquidia Technologies hisseleri yasal zaferle y\u00fckseliyor","h1_source":{"label":"H1","type":"text","formatted_value":"Liquidia Technologies hisseleri yasal zaferle y\u00fckseliyor"},"description":"Liquidia Technologies, mahkeme karar\u0131 sonras\u0131 pulmoner hipertansiyon tedavisinin ilerlemesi i\u00e7in yol a\u00e7\u0131lmas\u0131yla hisse senedi fiyat\u0131nda dramatik bir art\u0131\u015f ya\u015f\u0131yor.","description_source":{"label":"Description","type":"textarea","formatted_value":"Liquidia Technologies, mahkeme karar\u0131 sonras\u0131 pulmoner hipertansiyon tedavisinin ilerlemesi i\u00e7in yol a\u00e7\u0131lmas\u0131yla hisse senedi fiyat\u0131nda dramatik bir art\u0131\u015f ya\u015f\u0131yor."},"intro":"\u0130la\u00e7 end\u00fcstrisinde \u00f6nemli bir geli\u015fme, daha k\u00fc\u00e7\u00fck bir biyofarmas\u00f6tik \u015firketin \u00f6nemli bir yasal zafer kazanmas\u0131yla ortaya \u00e7\u0131kt\u0131 ve bu durum, \u015firketin pazar konumunu ve \u00fcr\u00fcn geli\u015ftirme beklentilerini \u00f6nemli \u00f6l\u00e7\u00fcde iyile\u015ftirdi.","intro_source":{"label":"Intro","type":"text","formatted_value":"\u0130la\u00e7 end\u00fcstrisinde \u00f6nemli bir geli\u015fme, daha k\u00fc\u00e7\u00fck bir biyofarmas\u00f6tik \u015firketin \u00f6nemli bir yasal zafer kazanmas\u0131yla ortaya \u00e7\u0131kt\u0131 ve bu durum, \u015firketin pazar konumunu ve \u00fcr\u00fcn geli\u015ftirme beklentilerini \u00f6nemli \u00f6l\u00e7\u00fcde iyile\u015ftirdi."},"body_html":" \n\nLiquidia Technologies, patent anla\u015fmazl\u0131\u011f\u0131nda olumlu bir mahkeme karar\u0131 sonras\u0131nda \u00c7ar\u015famba g\u00fcn\u00fc dikkat \u00e7ekici bir hisse senedi fiyat\u0131 art\u0131\u015f\u0131 ya\u015fad\u0131 ve bu, \u015firketin pulmoner arteriyel hipertansiyon (PAH) tedavisinin \u00f6n\u00fcn\u00fc a\u00e7t\u0131.\n

Hisse Performans\u0131 ve Piyasa Tepkisi<\/h2>\nBiyofarmas\u00f6tik firman\u0131n hisseleri, yasal geli\u015fmeye yat\u0131r\u0131mc\u0131lar\u0131n olumlu tepkisini yans\u0131tarak, g\u00fcn ortas\u0131 i\u015flemlerinde %36'l\u0131k etkileyici bir art\u0131\u015f g\u00f6sterdi. Hisse ba\u015f\u0131na 15,54 dolara ula\u015farak, son d\u00f6nemdeki en \u00f6nemli tek g\u00fcnl\u00fck kazan\u00e7lar\u0131ndan birini temsil etti.\n\nBu dramatik fiyat hareketi, \u015firketin hisselerinin mahkemelerde ilerleyen patent davalar\u0131 nedeniyle \u00f6nemli dalgalanmalar ya\u015fad\u0131\u011f\u0131 bir belirsizlik d\u00f6neminin ard\u0131ndan geldi. Ticaret hacmi de normal seviyelerin olduk\u00e7a \u00fczerine \u00e7\u0131karak, duyurunun ard\u0131ndan artan yat\u0131r\u0131mc\u0131 ilgisini g\u00f6sterdi.\n

Yasal Zafer Detaylar\u0131<\/h2>\nHisse fiyat\u0131ndaki art\u0131\u015f, Amerika Birle\u015fik Devletleri Federal Devre Temyiz Mahkemesi'nin United Therapeutics'in temyizini reddetmesinin ard\u0131ndan geldi ve bu, iki ila\u00e7 \u015firketi aras\u0131ndaki devam eden patent anla\u015fmazl\u0131\u011f\u0131nda Liquidia lehine \u00f6nceki bir karar\u0131 etkili bir \u015fekilde onaylad\u0131.\n\nBu yasal zafer, Liquidia'n\u0131n PAH hastalar\u0131 i\u00e7in tasarlanm\u0131\u015f treprostinil bazl\u0131 bir tedavi olan YUTREPIA inhalasyon tozunu ilerletme yetene\u011fini engelleyen \u00f6nemli bir engeli ortadan kald\u0131r\u0131yor. Mahkemenin karar\u0131, Liquidia'n\u0131n \u00fcr\u00fcn\u00fcn\u00fcn United Therapeutics'in patentlerini ihlal etmedi\u011fi y\u00f6n\u00fcndeki pozisyonunu esasen do\u011fruluyor.\n\nKarar, Liquidia i\u00e7in \u00f6nemli bir geli\u015fmeyi temsil ediyor, \u00e7\u00fcnk\u00fc \u015firketin yat\u0131r\u0131mc\u0131 g\u00fcvenini ve stratejik planlamay\u0131 daha \u00f6nce engelleyen yasal bulut olmadan ticarile\u015ftirme planlar\u0131na devam etmesine olanak tan\u0131yor.\n

Tedavi Pazar\u0131n\u0131n \u00d6nemi<\/h2>\nYUTREPIA, analistlerin k\u00fcresel olarak yakla\u015f\u0131k 5 milyar dolar de\u011ferinde oldu\u011funu belirtti\u011fi PAH tedavi pazar\u0131nda \u00f6nemli bir potansiyel giri\u015f temsil ediyor. Tedavi, akci\u011ferlerin arterlerinde y\u00fcksek tansiyona neden olan bu nadir ama ciddi durumdan muzdarip hastalar i\u00e7in sonu\u00e7lar\u0131 iyile\u015ftirmek \u00fczere tasarlanm\u0131\u015ft\u0131r.\n\n\u0130nhalasyon tozu form\u00fclasyonu, belirli hasta pop\u00fclasyonlar\u0131 i\u00e7in potansiyel olarak geli\u015ftirilmi\u015f terap\u00f6tik profiller ve uygulama kolayl\u0131\u011f\u0131 dahil olmak \u00fczere mevcut tedavilere g\u00f6re potansiyel avantajlar sunmaktad\u0131r.\n\nUnited Therapeutics \u015fu anda ge\u00e7en y\u0131l 1 milyar dolardan fazla sat\u0131\u015f yapan ba\u015fka bir treprostinil bazl\u0131 inhalasyon tedavisi olan Tyvaso'yu pazarl\u0131yor ve bu da Liquidia'n\u0131n rakip \u00fcr\u00fcn\u00fcn\u00fcn ticari potansiyelini vurguluyor.\n

Y\u00f6netici Yorumlar\u0131<\/h2>\nLiquidia'n\u0131n liderli\u011fi, mahkemenin karar\u0131ndan memnuniyetini dile getirerek, bunun \u015firketin gelecekteki beklentileri i\u00e7in \u00f6nemini vurgulad\u0131.\n\n\"Federal Devre Temyiz Mahkemesi'nin bug\u00fcnk\u00fc karar\u0131, her zaman bildi\u011fimiz \u015feyi do\u011fruluyor - Liquidia, YUTREPIA'y\u0131 geli\u015ftirirken do\u011fru davrand\u0131 ve bu \u00f6nemli yeni \u00fcr\u00fcn\u00fc PAH hastalar\u0131na sunma hakk\u0131na sahibiz,\" dedi Liquidia'n\u0131n \u0130cra Kurulu Ba\u015fkan\u0131 Dr. Roger Jeffs.\n\nEkledi, \"Bu karar \u00f6nemli bir engeli ortadan kald\u0131r\u0131yor ve bizi yakla\u015fan lansman haz\u0131rl\u0131klar\u0131m\u0131za tam olarak odaklanmam\u0131za olanak tan\u0131yor. PAH hastalar\u0131na ya\u015fam kalitelerini anlaml\u0131 bir \u015fekilde iyile\u015ftirebilecek yenilik\u00e7i bir tedavi se\u00e7ene\u011fi sunmaya kararl\u0131y\u0131z.\"\n\n[cta_button text=\"Start Trading\"]\n

D\u00fczenleyici Durum ve Ticari G\u00f6r\u00fcn\u00fcm<\/h2>\nLiquidia, Kas\u0131m 2021'de YUTREPIA i\u00e7in G\u0131da ve \u0130la\u00e7 \u0130daresi'nden (FDA) ge\u00e7ici onay ald\u0131, ancak tam ticari lansman, United Therapeutics ile olan patent davas\u0131n\u0131n \u00e7\u00f6z\u00fclmesini beklerken ertelendi.\n\nBu yasal engelin \u015fimdi a\u015f\u0131lmas\u0131yla, analistler \u015firketin lansman haz\u0131rl\u0131klar\u0131na devam edece\u011fini ve nihai FDA onay\u0131na tabi olarak \u00f6n\u00fcm\u00fczdeki aylarda potansiyel pazar giri\u015finin m\u00fcmk\u00fcn olabilece\u011fini tahmin ediyor.\n\n\u015eirketi takip eden finansal analistler, gelir projeksiyonlar\u0131n\u0131 yukar\u0131 y\u00f6nl\u00fc revize etmeye ba\u015flad\u0131lar ve birka\u00e7 analist, YUTREPIA'n\u0131n form\u00fclasyonu ve teslimat avantajlar\u0131 g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda PAH tedavi pazar\u0131n\u0131n \u00f6nemli bir pay\u0131n\u0131 potansiyel olarak ele ge\u00e7irebilece\u011fini belirtti.\n\n\u015eirket, dava s\u00fcresince \u00fcretim kapasitesini art\u0131rarak ve olumlu bir yasal sonu\u00e7 beklentisiyle pazarlama altyap\u0131s\u0131n\u0131 kurarak ticari bir lansman\u0131 ger\u00e7ekle\u015ftirmeye iyi bir \u015fekilde haz\u0131r oldu\u011funu belirtti.\n\nSekt\u00f6r g\u00f6zlemcileri, bu davan\u0131n, patent davalar\u0131n\u0131n daha k\u00fc\u00e7\u00fck ila\u00e7 \u015firketlerinin piyasa de\u011ferlemeleri ve ticari beklentileri \u00fczerinde \u00f6nemli bir etkiye sahip olabilece\u011finin \u00f6nemli bir \u00f6rne\u011fini temsil etti\u011fini ve bug\u00fcnk\u00fc \u00f6nemli hisse hareketinin biyofarmas\u00f6tik sekt\u00f6rde fikri m\u00fclkiyet korumas\u0131n\u0131n maddi \u00f6nemini yans\u0131tt\u0131\u011f\u0131n\u0131 belirtiyor.","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"

 <\/p>\n

Liquidia Technologies, patent anla\u015fmazl\u0131\u011f\u0131nda olumlu bir mahkeme karar\u0131 sonras\u0131nda \u00c7ar\u015famba g\u00fcn\u00fc dikkat \u00e7ekici bir hisse senedi fiyat\u0131 art\u0131\u015f\u0131 ya\u015fad\u0131 ve bu, \u015firketin pulmoner arteriyel hipertansiyon (PAH) tedavisinin \u00f6n\u00fcn\u00fc a\u00e7t\u0131.<\/p>\n

Hisse Performans\u0131 ve Piyasa Tepkisi<\/h2>\n

Biyofarmas\u00f6tik firman\u0131n hisseleri, yasal geli\u015fmeye yat\u0131r\u0131mc\u0131lar\u0131n olumlu tepkisini yans\u0131tarak, g\u00fcn ortas\u0131 i\u015flemlerinde %36’l\u0131k etkileyici bir art\u0131\u015f g\u00f6sterdi. Hisse ba\u015f\u0131na 15,54 dolara ula\u015farak, son d\u00f6nemdeki en \u00f6nemli tek g\u00fcnl\u00fck kazan\u00e7lar\u0131ndan birini temsil etti.<\/p>\n

Bu dramatik fiyat hareketi, \u015firketin hisselerinin mahkemelerde ilerleyen patent davalar\u0131 nedeniyle \u00f6nemli dalgalanmalar ya\u015fad\u0131\u011f\u0131 bir belirsizlik d\u00f6neminin ard\u0131ndan geldi. Ticaret hacmi de normal seviyelerin olduk\u00e7a \u00fczerine \u00e7\u0131karak, duyurunun ard\u0131ndan artan yat\u0131r\u0131mc\u0131 ilgisini g\u00f6sterdi.<\/p>\n

Yasal Zafer Detaylar\u0131<\/h2>\n

Hisse fiyat\u0131ndaki art\u0131\u015f, Amerika Birle\u015fik Devletleri Federal Devre Temyiz Mahkemesi’nin United Therapeutics’in temyizini reddetmesinin ard\u0131ndan geldi ve bu, iki ila\u00e7 \u015firketi aras\u0131ndaki devam eden patent anla\u015fmazl\u0131\u011f\u0131nda Liquidia lehine \u00f6nceki bir karar\u0131 etkili bir \u015fekilde onaylad\u0131.<\/p>\n

Bu yasal zafer, Liquidia’n\u0131n PAH hastalar\u0131 i\u00e7in tasarlanm\u0131\u015f treprostinil bazl\u0131 bir tedavi olan YUTREPIA inhalasyon tozunu ilerletme yetene\u011fini engelleyen \u00f6nemli bir engeli ortadan kald\u0131r\u0131yor. Mahkemenin karar\u0131, Liquidia’n\u0131n \u00fcr\u00fcn\u00fcn\u00fcn United Therapeutics’in patentlerini ihlal etmedi\u011fi y\u00f6n\u00fcndeki pozisyonunu esasen do\u011fruluyor.<\/p>\n

Karar, Liquidia i\u00e7in \u00f6nemli bir geli\u015fmeyi temsil ediyor, \u00e7\u00fcnk\u00fc \u015firketin yat\u0131r\u0131mc\u0131 g\u00fcvenini ve stratejik planlamay\u0131 daha \u00f6nce engelleyen yasal bulut olmadan ticarile\u015ftirme planlar\u0131na devam etmesine olanak tan\u0131yor.<\/p>\n

Tedavi Pazar\u0131n\u0131n \u00d6nemi<\/h2>\n

YUTREPIA, analistlerin k\u00fcresel olarak yakla\u015f\u0131k 5 milyar dolar de\u011ferinde oldu\u011funu belirtti\u011fi PAH tedavi pazar\u0131nda \u00f6nemli bir potansiyel giri\u015f temsil ediyor. Tedavi, akci\u011ferlerin arterlerinde y\u00fcksek tansiyona neden olan bu nadir ama ciddi durumdan muzdarip hastalar i\u00e7in sonu\u00e7lar\u0131 iyile\u015ftirmek \u00fczere tasarlanm\u0131\u015ft\u0131r.<\/p>\n

\u0130nhalasyon tozu form\u00fclasyonu, belirli hasta pop\u00fclasyonlar\u0131 i\u00e7in potansiyel olarak geli\u015ftirilmi\u015f terap\u00f6tik profiller ve uygulama kolayl\u0131\u011f\u0131 dahil olmak \u00fczere mevcut tedavilere g\u00f6re potansiyel avantajlar sunmaktad\u0131r.<\/p>\n

United Therapeutics \u015fu anda ge\u00e7en y\u0131l 1 milyar dolardan fazla sat\u0131\u015f yapan ba\u015fka bir treprostinil bazl\u0131 inhalasyon tedavisi olan Tyvaso’yu pazarl\u0131yor ve bu da Liquidia’n\u0131n rakip \u00fcr\u00fcn\u00fcn\u00fcn ticari potansiyelini vurguluyor.<\/p>\n

Y\u00f6netici Yorumlar\u0131<\/h2>\n

Liquidia’n\u0131n liderli\u011fi, mahkemenin karar\u0131ndan memnuniyetini dile getirerek, bunun \u015firketin gelecekteki beklentileri i\u00e7in \u00f6nemini vurgulad\u0131.<\/p>\n

“Federal Devre Temyiz Mahkemesi’nin bug\u00fcnk\u00fc karar\u0131, her zaman bildi\u011fimiz \u015feyi do\u011fruluyor – Liquidia, YUTREPIA’y\u0131 geli\u015ftirirken do\u011fru davrand\u0131 ve bu \u00f6nemli yeni \u00fcr\u00fcn\u00fc PAH hastalar\u0131na sunma hakk\u0131na sahibiz,” dedi Liquidia’n\u0131n \u0130cra Kurulu Ba\u015fkan\u0131 Dr. Roger Jeffs.<\/p>\n

Ekledi, “Bu karar \u00f6nemli bir engeli ortadan kald\u0131r\u0131yor ve bizi yakla\u015fan lansman haz\u0131rl\u0131klar\u0131m\u0131za tam olarak odaklanmam\u0131za olanak tan\u0131yor. PAH hastalar\u0131na ya\u015fam kalitelerini anlaml\u0131 bir \u015fekilde iyile\u015ftirebilecek yenilik\u00e7i bir tedavi se\u00e7ene\u011fi sunmaya kararl\u0131y\u0131z.”<\/p>\n

\n \n \n <\/use>\n <\/svg>\n Start Trading<\/span>\n <\/a>\n <\/div>\n \n

D\u00fczenleyici Durum ve Ticari G\u00f6r\u00fcn\u00fcm<\/h2>\n

Liquidia, Kas\u0131m 2021’de YUTREPIA i\u00e7in G\u0131da ve \u0130la\u00e7 \u0130daresi’nden (FDA) ge\u00e7ici onay ald\u0131, ancak tam ticari lansman, United Therapeutics ile olan patent davas\u0131n\u0131n \u00e7\u00f6z\u00fclmesini beklerken ertelendi.<\/p>\n

Bu yasal engelin \u015fimdi a\u015f\u0131lmas\u0131yla, analistler \u015firketin lansman haz\u0131rl\u0131klar\u0131na devam edece\u011fini ve nihai FDA onay\u0131na tabi olarak \u00f6n\u00fcm\u00fczdeki aylarda potansiyel pazar giri\u015finin m\u00fcmk\u00fcn olabilece\u011fini tahmin ediyor.<\/p>\n

\u015eirketi takip eden finansal analistler, gelir projeksiyonlar\u0131n\u0131 yukar\u0131 y\u00f6nl\u00fc revize etmeye ba\u015flad\u0131lar ve birka\u00e7 analist, YUTREPIA’n\u0131n form\u00fclasyonu ve teslimat avantajlar\u0131 g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda PAH tedavi pazar\u0131n\u0131n \u00f6nemli bir pay\u0131n\u0131 potansiyel olarak ele ge\u00e7irebilece\u011fini belirtti.<\/p>\n

\u015eirket, dava s\u00fcresince \u00fcretim kapasitesini art\u0131rarak ve olumlu bir yasal sonu\u00e7 beklentisiyle pazarlama altyap\u0131s\u0131n\u0131 kurarak ticari bir lansman\u0131 ger\u00e7ekle\u015ftirmeye iyi bir \u015fekilde haz\u0131r oldu\u011funu belirtti.<\/p>\n

Sekt\u00f6r g\u00f6zlemcileri, bu davan\u0131n, patent davalar\u0131n\u0131n daha k\u00fc\u00e7\u00fck ila\u00e7 \u015firketlerinin piyasa de\u011ferlemeleri ve ticari beklentileri \u00fczerinde \u00f6nemli bir etkiye sahip olabilece\u011finin \u00f6nemli bir \u00f6rne\u011fini temsil etti\u011fini ve bug\u00fcnk\u00fc \u00f6nemli hisse hareketinin biyofarmas\u00f6tik sekt\u00f6rde fikri m\u00fclkiyet korumas\u0131n\u0131n maddi \u00f6nemini yans\u0131tt\u0131\u011f\u0131n\u0131 belirtiyor.<\/p>\n"},"faq":null,"faq_source":{"label":"FAQ","type":"repeater","formatted_value":false}},"yoast_head":"\nBiyofarmas\u00f6tik Firman\u0131n Hisseleri Olumlu Patent Karar\u0131n\u0131n Ard\u0131ndan Y\u00fckseldi<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biyofarmas\u00f6tik Firman\u0131n Hisseleri Olumlu Patent Karar\u0131n\u0131n Ard\u0131ndan Y\u00fckseldi\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-15T21:37:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Biopharmaceutical-Firms-Shares-Soar-Following-Favorable-Patent-Ruling.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1840\" \/>\n\t<meta property=\"og:image:height\" content=\"700\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Andrew OK\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Andrew OK\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/\"},\"author\":{\"name\":\"Andrew OK\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/8c927d60ff98b0ebe00861e922a035d3\"},\"headline\":\"Biyofarmas\u00f6tik Firman\u0131n Hisseleri Olumlu Patent Karar\u0131n\u0131n Ard\u0131ndan Y\u00fckseldi\",\"datePublished\":\"2025-07-15T21:37:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/\"},\"wordCount\":14,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Biopharmaceutical-Firms-Shares-Soar-Following-Favorable-Patent-Ruling.webp\",\"keywords\":[\"investment\",\"platform\",\"signal\"],\"articleSection\":[\"News\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/\",\"name\":\"Biyofarmas\u00f6tik Firman\u0131n Hisseleri Olumlu Patent Karar\u0131n\u0131n Ard\u0131ndan Y\u00fckseldi\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Biopharmaceutical-Firms-Shares-Soar-Following-Favorable-Patent-Ruling.webp\",\"datePublished\":\"2025-07-15T21:37:51+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/8c927d60ff98b0ebe00861e922a035d3\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Biopharmaceutical-Firms-Shares-Soar-Following-Favorable-Patent-Ruling.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Biopharmaceutical-Firms-Shares-Soar-Following-Favorable-Patent-Ruling.webp\",\"width\":1840,\"height\":700},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biyofarmas\u00f6tik Firman\u0131n Hisseleri Olumlu Patent Karar\u0131n\u0131n Ard\u0131ndan Y\u00fckseldi\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/8c927d60ff98b0ebe00861e922a035d3\",\"name\":\"Andrew OK\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/383d2c0dd4b219f690be51029697edeb43831adb70c4cbf4f9500ec37448a792?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/383d2c0dd4b219f690be51029697edeb43831adb70c4cbf4f9500ec37448a792?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/383d2c0dd4b219f690be51029697edeb43831adb70c4cbf4f9500ec37448a792?s=96&d=mm&r=g\",\"caption\":\"Andrew OK\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/andrew-ok\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biyofarmas\u00f6tik Firman\u0131n Hisseleri Olumlu Patent Karar\u0131n\u0131n Ard\u0131ndan Y\u00fckseldi","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/","og_locale":"tr_TR","og_type":"article","og_title":"Biyofarmas\u00f6tik Firman\u0131n Hisseleri Olumlu Patent Karar\u0131n\u0131n Ard\u0131ndan Y\u00fckseldi","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/","og_site_name":"Pocket Option blog","article_published_time":"2025-07-15T21:37:51+00:00","og_image":[{"width":1840,"height":700,"url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Biopharmaceutical-Firms-Shares-Soar-Following-Favorable-Patent-Ruling.webp","type":"image\/webp"}],"author":"Andrew OK","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Andrew OK"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/"},"author":{"name":"Andrew OK","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/8c927d60ff98b0ebe00861e922a035d3"},"headline":"Biyofarmas\u00f6tik Firman\u0131n Hisseleri Olumlu Patent Karar\u0131n\u0131n Ard\u0131ndan Y\u00fckseldi","datePublished":"2025-07-15T21:37:51+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/"},"wordCount":14,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Biopharmaceutical-Firms-Shares-Soar-Following-Favorable-Patent-Ruling.webp","keywords":["investment","platform","signal"],"articleSection":["News"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/","name":"Biyofarmas\u00f6tik Firman\u0131n Hisseleri Olumlu Patent Karar\u0131n\u0131n Ard\u0131ndan Y\u00fckseldi","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Biopharmaceutical-Firms-Shares-Soar-Following-Favorable-Patent-Ruling.webp","datePublished":"2025-07-15T21:37:51+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/8c927d60ff98b0ebe00861e922a035d3"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Biopharmaceutical-Firms-Shares-Soar-Following-Favorable-Patent-Ruling.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Biopharmaceutical-Firms-Shares-Soar-Following-Favorable-Patent-Ruling.webp","width":1840,"height":700},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Biyofarmas\u00f6tik Firman\u0131n Hisseleri Olumlu Patent Karar\u0131n\u0131n Ard\u0131ndan Y\u00fckseldi"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/8c927d60ff98b0ebe00861e922a035d3","name":"Andrew OK","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/383d2c0dd4b219f690be51029697edeb43831adb70c4cbf4f9500ec37448a792?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/383d2c0dd4b219f690be51029697edeb43831adb70c4cbf4f9500ec37448a792?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/383d2c0dd4b219f690be51029697edeb43831adb70c4cbf4f9500ec37448a792?s=96&d=mm&r=g","caption":"Andrew OK"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/andrew-ok\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":307584,"slug":"biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling","post_title":"C\u1ed5 phi\u1ebfu c\u1ee7a C\u00f4ng ty D\u01b0\u1ee3c ph\u1ea9m Sinh h\u1ecdc T\u0103ng V\u1ecdt Sau Ph\u00e1n Quy\u1ebft B\u1eb1ng S\u00e1ng Ch\u1ebf Thu\u1eadn L\u1ee3i","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/"},"pt_AA":{"locale":"pt_AA","id":307579,"slug":"biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling","post_title":"As a\u00e7\u00f5es da empresa biofarmac\u00eautica disparam ap\u00f3s decis\u00e3o favor\u00e1vel sobre patente","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/307582","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/45"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=307582"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/307582\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/307568"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=307582"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=307582"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=307582"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}